Get notified when GRML files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Standing Risk Factors

  • Going Concern (unchanged) — Substantial doubt about the company's ability to continue as a going concern persists; cash position ($7.2M) and accumulated deficit ($21.1M) unchanged from the original 10-K.
  • Material Weakness (unchanged) — Material weaknesses in internal controls remain, attributed to inadequate accounting resources, lack of segregation of duties, and need for a stronger control environment.
NASDAQ: GRML Greenland Mines Ltd 10-K/A

GRML 10-K/A reclassifies share-based comp, adds expense detail; KLTO-202 IND pushed to 2027

Filed August 14, 2026 · Period ending December 31, 2025 · Compared to 10-K Apr 1, 2026 · ~2 min read

Key Financials

SEC XBRL

Period financials are unchanged from the original 10-K (same period end Dec 31, 2025). This amendment updates disclosure only — see the diff below.

Key Changes

  • high

    KLTO-202 (ALS candidate) IND submission and first-in-human study delayed from 2025 to 2027, a two-year slip attributed to delays in obtaining the human construct from UAB and inventors, which impacted manufacturing and toxicology studies.

    Business: KLTO-202 IND timeline verify on EDGAR →
  • high

    KLTO-101 (Alzheimer's candidate) product construct updated from AAV9-CMV-sKL to AAV9*ShD-CAD-sKL, incorporating AAVnerGene's AAVShD delivery technology shown in non-human primates to optimize blood-brain-barrier crossing for CNS delivery.

    Business: KLTO-101 product construct verify on EDGAR →
  • medium

    10-K/A reclassifies $1.6M of share-based compensation from a separate line into General and administrative expense; total operating expenses and net loss unchanged at $7.1M and $10.6M respectively. Amendment adds detailed breakdowns of professional fees ($675K increase driven by$$347K in transaction-related advisory costs), G&A ($297K increase driven by $1.13M in new personnel costs offset by $1.08M drop in stock comp), and R&D ($634K increase split between $484K for UAB/Okinawa sponsored research and $150K for AAVnerGene vector work).

    MD&A: Operating-expense disclosure; Notes: Presentation reclassification verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (ZEO 10-Q) is open in full — no account needed.

Partner

Trade GRML commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Aug 17, 2026 · How we verify